Coya Therapeutics Inc (COYA)

$6.18 -0.35 (-5.36%)
Market Cap 109.21M
Revenue (ttm) 3.55M
Net Income (ttm) -14.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -419.15%
Debt to Equity Ratio 0.00
Volume 43,300
Avg Vol 105,596
Day's Range N/A - N/A
Shares Out 16.73M
Stochastic %K 56%
Beta 0.49
Analysts Strong Sell
Price Target $16.25

Latest News on COYA

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release

Apr 25, 2025, 11:27 AM EDT - 17 hours ago

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Apr 24, 2025, 8:15 AM EDT - 1 day ago

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Apr 21, 2025, 9:51 AM EDT - 4 days ago

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Apr 1, 2025, 8:15 AM EDT - 24 days ago

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Mar 26, 2025, 8:15 AM EDT - 4 weeks ago

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Mar 18, 2025, 8:15 AM EDT - 5 weeks ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Feb 25, 2025, 8:15 AM EST - 2 months ago

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Feb 7, 2025, 5:17 PM EST - 2 months ago

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Feb 7, 2025, 1:53 PM EST - 2 months ago

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Feb 6, 2025, 1:30 PM EST - 2 months ago

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Feb 6, 2025, 8:00 AM EST - 2 months ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:15 AM EST - 2 months ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Jan 21, 2025, 8:15 AM EST - 3 months ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Dec 18, 2024, 8:15 AM EST - 4 months ago

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Nov 25, 2024, 8:15 AM EST - 5 months ago

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Nov 19, 2024, 8:15 AM EST - 5 months ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Nov 6, 2024, 8:00 AM EST - 6 months ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Nov 1, 2024, 8:15 AM EDT - 6 months ago

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Oct 31, 2024, 10:31 AM EDT - 6 months ago

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Oct 29, 2024, 2:36 PM EDT - 6 months ago

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Oct 29, 2024, 6:41 AM EDT - 6 months ago

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)

Oct 29, 2024, 6:30 AM EDT - 6 months ago

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

Oct 28, 2024, 8:00 AM EDT - 6 months ago

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

Coya Therapeutics Announces Closing of $10.0 Million Private Placement

Oct 23, 2024, 4:05 PM EDT - 6 months ago

Coya Therapeutics Announces Closing of $10.0 Million Private Placement

Coya Therapeutics Announces $10.0 Million Private Placement

Oct 22, 2024, 9:00 AM EDT - 6 months ago

Coya Therapeutics Announces $10.0 Million Private Placement

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Oct 13, 2024, 4:17 AM EDT - 6 months ago

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100

Oct 8, 2024, 9:15 AM EDT - 7 months ago

Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100

Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference

Sep 24, 2024, 8:15 AM EDT - 7 months ago

Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference

Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's Disease

Sep 16, 2024, 8:15 AM EDT - 7 months ago

Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's Disease

Coya Therapeutics to Present at Upcoming Healthcare Conferences

Sep 3, 2024, 8:15 AM EDT - 8 months ago

Coya Therapeutics to Present at Upcoming Healthcare Conferences

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024

Aug 19, 2024, 9:00 AM EDT - 8 months ago

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results

Aug 12, 2024, 8:00 AM EDT - 9 months ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results

Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid

Aug 2, 2024, 8:15 AM EDT - 9 months ago

Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Jul 31, 2024, 8:15 AM EDT - 9 months ago

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic

Jun 20, 2024, 8:15 AM EDT - 11 months ago

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology

Jun 11, 2024, 8:15 AM EDT - 11 months ago

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology

Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer

Jun 10, 2024, 2:55 PM EDT - 11 months ago

Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology

Jun 3, 2024, 8:15 AM EDT - 11 months ago

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology

Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index

May 28, 2024, 8:15 AM EDT - 11 months ago

Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index

Coya Therapeutics (COYA) CEO on $5M Alzheimer's Drug Discovery Foundation Investment

May 23, 2024, 3:40 PM EDT - 1 year ago

Coya Therapeutics (COYA) CEO on $5M Alzheimer's Drug Discovery Foundation Investment

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease

May 22, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease

Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)

May 20, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

May 9, 2024, 4:10 PM EDT - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseases

May 1, 2024, 6:45 AM EDT - 1 year ago

Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseases

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Apr 26, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Coya Therapeutics to Participate in the Mizuho Neuroscience Summit

Apr 22, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Participate in the Mizuho Neuroscience Summit

Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit

Apr 18, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Apr 8, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

Mar 19, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

Coya Therapeutics to Participate in BTIG Fireside Discussion

Mar 12, 2024, 9:00 AM EDT - 1 year ago

Coya Therapeutics to Participate in BTIG Fireside Discussion